PINEHURST – Lung cancer is the foremost cause of death from cancer in North Carolina. Non-small cell lung cancer (NSCLC) accounts for 80 percent of cases and half of these patients have metastatic disease at first diagnosis.
One of the major challenges in the treatment of advanced lung cancer is to balance effectiveness and tolerability of treatment. Currently, it is difficult to know how various regimens for treating advanced NSCLC compare in terms of the experiences that patients can self-report. There is a need to obtain more information about how patients actually experience different regimens for advanced NSCLC in the field.
A new quality-of-life research study at FirstHealth Moore Regional Hospital will observe participating patients to look at side effects of cancer treatment, the effectiveness of different types of treatment and health-related quality of life.
Participants are eligible to participate in the research trial if they are at least 18 years old and are not being treated for another cancer (with the exception of basal cell carcinoma).
For more information on the trial and eligibility, contact the FirstHealth Clinical Trials office at (910) 715-2200 or principal investigator Charles Kuzma, M.D., at (910) 715-3500 or visit www.firsthealth.org/clinicaltrials.
October 7, 2016
FirstHealth to “Shine a Light” on Lung Cancer with Nov. 2 VigilPINEHURST – According to the American Cancer Society, a man has a 1 in 14 chance of developing lung cancer in his lifetime. For women, the risk is 1…
October 4, 2016
Stand Together & Drink PinkRegister in the form provided to host your Drink Pink lemonade stand. To learn more about the Stand Together & Drink Pink campaign, click here. To do…
October 4, 2016
Stand Together & Drink PinkIf you are interested in a different, and tasty, way of increasing breast cancer awareness, join in as the community prepares to “Stand Together and…
April 5, 2017
CME: Small Intestinal Bacterial OvergrowthYou are invited to attend a program Small Intestinal Bacterial Overgrowth: Gastrointestinal and Systemic Manifestations, Plus Treatment April 5, 2017…